Adaptive Biotechnologies Corporation reports results for the quarter ended September 30 - Earnings Summary

What happened

Adaptive Biotechnologies reported adjusted earnings of 2 cents per share for the quarter ended September 30, down from 6 cents a year earlier and above analysts’ expected loss of 10 cents. Revenue fell 10.7% year over year to $83.90 million, exceeding the $71.60 million analyst expectation; net income was $2.88 million.

Confirmed

Global impact / market context

The company produced a small profit while revenue declined, but its earnings also fell from last year. Revenue coming in above analysts’ expectations may support confidence in sales, while the decline makes it important to see whether costs and future revenue can sustain profitability.

Analyst inference

Analysts’ average earnings estimate had risen about 4.4% over three months, with no revisions in the latest 30 days. The average rating was buy, and the median 12-month price target was $31.00 versus a last closing price of $25.80; these are analyst views, not guarantees.

Confirmed

What to watch

1. Watch upcoming quarterly results for whether revenue stabilizes or keeps falling, since sustained declines could reduce the income available to cover company costs. Analyst inference
2. Check whether adjusted earnings remain positive and how they compare with net income, because the two measures differ and can give investors different views of profitability. Analyst inference
3. Analysts had made no earnings estimate revisions in the last 30 days; check whether new forecasts change as analysts respond to subsequent company results. Confirmed

Evidence

• Original source link unavailable